Schreiner MediPharm Reports Needle-Trap Proves More Sustainable than Conventional Needle Safety Systems

Schreiner MediPharm, a Germany-based global provider of innovative functional label solutions for the healthcare industry, has investigated the comparable sustainability of its Needle-Trap safety solution relative to conventional needle safety systems. To evaluate the label’s sustainability, the pharma-label specialist conducted calculations comparing Needle-Trap with conventional needle safety systems.

Needle-Trap proved particularly environmentally friendly primarily due to its special design. Its plastic trap requires less plastic material than conventional needle safety systems and comprises up to 50 percent regranulated material. In addition, due to the label’s compact design, there is no need to adjust its secondary packaging. As a result, Needle-Trap requires less space during transportation and storage. It also generates less waste, which protects the environment and reduces the environmental footprint.

With sustainability playing an increasingly important role in the healthcare industry, it is incumbent upon manufacturers of all products – especially existing ones – to evaluate and optimize their solutions’ materials from an eco-conscious standpoint.

For the testing, calculations were made for 10 million units of one sort for a 1 ml long syringe, and represent best-case scenarios comparing the Needle-Trap label with typical needle safety systems, minus their included syringes. The results provide convincing data supporting Needle-Trap’s superior sustainability:
• 76 percent less space required in cargo containers
• 76 percent less transportation costs
• 80 – 83 percent less CO2 emissions during transport
• 6.6 – 12.7 tons of metal savings
• 37.6 – 53 tons of plastic savings

Furthermore, Needle-Trap’s needle protection label is delivered on rolls – eliminating the need for an additional blister pack – and the grid material waste from label production is recycled.

Consequently, Needle-Trap is a more eco-conscious solution compared with conventional needle safety systems while combining safety for healthcare professionals with cost efficiency for the pharmaceutical manufacturer.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”